Centre for Infectious Disease Research and Epidemiology, School of Public Health and Family Medicine, University of Cape Town, South Africa.
Clin Infect Dis. 2012 Dec;55(12):1698-706. doi: 10.1093/cid/cis775. Epub 2012 Sep 5.
Current symptom screening algorithms for intensified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human immunodeficiency virus (HIV) were derived from antiretroviral-naive cohorts. There is a need to validate screening algorithms in patients on antiretroviral therapy (ART).
We performed cross-sectional evaluation of the diagnostic accuracy of symptom screening, including the World Health Organization (WHO) algorithm, to rule out tuberculosis in HIV-infected individuals pre-ART and on ART undergoing screening prior to IPT.
A total of 1429 participants, 54% on ART, had symptom screening and a sputum culture result available. Culture-positive tuberculosis was diagnosed in 126 patients (8.8%, 95% confidence interval [CI], 7.4%-10.4%). The WHO symptom screen in the on-ART compared with the pre-ART group had a lower sensitivity (23.8% vs 47.6%), but higher specificity (94.4% vs 79.8%). The effect of ART was independent of CD4(+) count in multivariable analyses. The posttest probability of tuberculosis following a negative WHO screen was 8.9% (95% CI, 7.4%-10.8%) and 4.4% (95% CI, 3.7%-5.2%) for the pre-ART and on-ART groups, respectively. Addition of body mass index to the WHO screen significantly improved discriminatory ability in both ART groups, which was further improved by adding CD4 count and ART duration.
The WHO symptom screen has poor sensitivity, especially among patients on ART, in a clinic where regular tuberculosis screening is practiced. Consequently, a significant proportion of individuals with tuberculosis would inadvertently be placed on isoniazid monotherapy despite high negative predictive values. Until more sensitive methods of ruling out tuberculosis are established, it would be prudent to do a sputum culture prior to IPT where this is feasible.
目前用于强化结核病病例发现或人类免疫缺陷病毒(HIV)感染者异烟肼预防性治疗(IPT)之前的症状筛查算法均来自于未接受抗逆转录病毒治疗(ART)的队列。因此,有必要对接受抗逆转录病毒治疗(ART)的患者进行筛查算法验证。
我们对症状筛查的诊断准确性进行了横断面评估,包括世界卫生组织(WHO)算法,以排除 HIV 感染个体在 ART 前和接受 IPT 前筛查时的结核病。
共有 1429 名参与者,其中 54%正在接受 ART,他们的症状筛查和痰培养结果可用。诊断出 126 例(8.8%,95%置信区间[CI]:7.4%-10.4%)培养阳性结核病。与 ART 前组相比,ART 组的 WHO 症状筛查的敏感性较低(23.8%比 47.6%),但特异性较高(94.4%比 79.8%)。多变量分析表明,ART 的影响独立于 CD4(+)计数。在 WHO 筛查阴性后,结核病的 posttest 概率分别为 ART 前组的 8.9%(95%CI:7.4%-10.8%)和 ART 组的 4.4%(95%CI:3.7%-5.2%)。将体重指数添加到 WHO 筛查中可显著提高两组的鉴别能力,而添加 CD4 计数和 ART 持续时间则进一步提高了其鉴别能力。
在经常进行结核病筛查的诊所中,WHO 症状筛查的敏感性较差,尤其是在接受 ART 的患者中。因此,尽管阴性预测值较高,但会无意中将相当一部分结核病患者置于异烟肼单药治疗中。在可行的情况下,在开始 IPT 之前进行痰培养可能是一种谨慎的做法,直到建立更敏感的排除结核病的方法。